Verbascum Thapsus

For diagnostic purposes, the dosage of Verbascum Thapsus is not measured in milligrams but in volume and concentration.

• Percutaneous Testing (Prick/Puncture): One drop of the concentrate (typically 1:10 or 1:20 w/v) is applied to the skin, followed by a prick through the drop. Results are read at 15–20 minutes.
• Intradermal Testing: If the prick test is negative, a dose of 0.02 mL to 0.05 mL of a 1:100 or 1:1000 dilution may be injected into the dermis.
• Immunotherapy: The starting dose is usually 0.1 mL of a very high dilution (e.g., 1:100,000), increasing weekly by 0.1 mL until a maintenance dose is reached, typically 0.5 mL of a 1:10 or 1:20 concentrate.

Verbascum Thapsus extracts are approved for use in children; however, extreme caution is required. Pediatric dosing follows the same escalation protocol as adult dosing, but the starting concentration may be further diluted based on the child's sensitivity level. Children under the age of 5 require careful monitoring due to the difficulty in communicating early symptoms of systemic reactions.

Renal Impairment

No specific dose adjustments are required for skin testing in patients with renal impairment. However, for immunotherapy, patients with severe renal disease should be monitored for their ability to clear the metabolic byproducts of the inflammatory response triggered by the injection.

Hepatic Impairment

Because Verbascum Thapsus possesses Ammonium Ion Binding Activity, patients with hepatic impairment (liver failure) may actually benefit from its metabolic properties, but the allergenic use remains standard. No specific adjustments for skin testing are documented.

Elderly Patients

Elderly patients may have reduced skin reactivity (anergy). Therefore, a negative skin test in a patient over 65 may require further validation. Additionally, elderly patients on beta-blockers for hypertension are at higher risk if a reaction occurs.

Verbascum Thapsus allergenic extracts are strictly for professional administration.

• Preparation: The skin (usually the back or forearm) is cleaned with alcohol.
• Administration: The extract is applied via a sterile lancet or syringe.
• Observation: Patients MUST remain in the medical office for at least 30 minutes after administration to monitor for anaphylaxis.
• Storage: Extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Freezing must be avoided as it can denature the proteins, making the extract ineffective or dangerous.

In immunotherapy, if a dose is missed:

• 1 week late: Continue with the planned dose.
• 2–3 weeks late: The dose may need to be reduced to the previous level.
• Over 4 weeks late: The entire build-up process may need to be restarted from a lower concentration to prevent a severe reaction.

An overdose of Verbascum Thapsus extract usually manifests as a systemic allergic reaction. Signs include hives (urticaria), swelling of the throat (angioedema), wheezing, and a drop in blood pressure. Emergency treatment with epinephrine (Adrenalin) is required immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency of immunotherapy without medical guidance.

Most patients receiving Verbascum Thapsus for diagnostic or therapeutic purposes will experience localized reactions.

• Local Wheal and Flare: A small, itchy bump at the injection site that looks like a mosquito bite. This is a normal part of the diagnostic process.
• Injection Site Redness: Redness (erythema) that may spread 1–2 inches around the site.
• Pruritus (Itching): Intense itching at the site of administration, typically lasting 30 to 60 minutes.

• Delayed Local Reactions: Swelling and redness that appears 6 to 24 hours after the injection. These can be uncomfortable but are generally not dangerous.
• Fatigue: Some patients report feeling unusually tired for a few hours following immunotherapy.
• Headache: Mild to moderate tension-type headaches have been reported following systemic exposure to allergenic extracts.

• Lymphadenopathy: Swelling of the lymph nodes near the injection site.
• Vasovagal Reaction: Fainting or lightheadedness due to the needle stick rather than the extract itself.
• Persistent Granuloma: A small, hard knot under the skin at the injection site that may last for weeks.

> Warning: Stop taking Verbascum Thapsus and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Shortness of breath, wheezing, or a feeling of tightness in the chest.
• Upper Airway Obstruction: Swelling of the tongue or throat, or a hoarse voice.
• Cardiovascular Collapse: Rapid or weak pulse, dizziness, or sudden fainting.
• Generalized Urticaria: Hives spreading across the entire body, away from the injection site.
• Gastrointestinal Distress: Severe abdominal cramping, vomiting, or diarrhea occurring shortly after administration.

With prolonged immunotherapy (3–5 years), the primary long-term effect is the development of immunological tolerance. However, rare cases of serum sickness (an immune complex reaction) have been documented with high-dose, long-term allergenic extract therapy, manifesting as joint pain, fever, and rash.

While Verbascum Thapsus specifically may not have a unique black box warning, all allergenic extracts of this class carry a general warning regarding Anaphylaxis.

• Summary: This product can cause severe, life-threatening systemic reactions, including anaphylactic shock and death. It should only be administered by healthcare providers equipped with emergency resuscitation equipment and medications (epinephrine). Patients with unstable asthma are at increased risk for severe reactions.

Report any unusual symptoms to your healthcare provider immediately.

Verbascum Thapsus extract is a potent biological substance. It must never be self-administered by the patient. Safety depends on the accuracy of the dilution and the technique of administration. Patients must be screened for current health status before every dose; for example, if a patient is currently experiencing an asthma flare or has a fever, the dose should be withheld.

WARNING: RISK OF SEVERE ALLERGIC REACTION

• Verbascum Thapsus extracts are intended for use by physicians who are experienced in the administration of allergenic extracts and the management of anaphylaxis.
• Patients must be observed for at least 30 minutes following any injection.
• Severe reactions are more common in patients with symptomatic asthma or those receiving beta-blocker therapy.

• Allergic Reactions / Anaphylaxis: The primary risk is an IgE-mediated systemic reaction. This can occur even if the patient has tolerated previous doses.
• Asthma Exacerbation: Patients with poorly controlled asthma are at a significantly higher risk of a fatal reaction. Pulmonary function (Peak Flow) should be checked before administration in asthmatic patients.
• Autoimmune Disorders: Use with caution in patients with active autoimmune diseases, as immunotherapy may theoretically exacerbate these conditions.
• Malignancy: There is limited data on the use of allergenic extracts in patients with active cancer; a risk-benefit analysis is required.

• Observation: 30-minute post-injection clinical observation is mandatory.
• Skin Reaction Measurement: In diagnostic testing, the diameter of the wheal and flare must be measured and recorded in millimeters.
• Vital Signs: Blood pressure and heart rate should be monitored if the patient feels unwell.

Generally, Verbascum Thapsus does not cause sedation. However, if a patient experiences a vasovagal reaction (fainting) or a mild systemic reaction, they should not drive until symptoms have completely resolved and they have been cleared by a physician.

Alcohol consumption should be avoided on the day of an immunotherapy injection. Alcohol can cause vasodilation (widening of blood vessels), which may increase the rate of absorption of the allergen and potentially increase the severity of a systemic reaction.

Discontinuation of Verbascum Thapsus immunotherapy does not require a tapering period. However, the protective effects against allergies will gradually diminish over months or years if the maintenance course is not completed (typically 3–5 years).

> Important: Discuss all your medical conditions with your healthcare provider before starting Verbascum Thapsus.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are contraindicated in patients receiving Verbascum Thapsus immunotherapy. The reason is that beta-blockers interfere with the action of epinephrine (Adrenalin). If the patient has an anaphylactic reaction, epinephrine may be ineffective, leading to a potentially fatal outcome.

• ACE Inhibitors (e.g., Lisinopril): These drugs may increase the risk of systemic reactions or worsen the severity of angioedema (swelling) during allergen exposure.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of sympathomimetic amines used to treat reactions, leading to hypertensive crises.

• Antihistamines (e.g., Loratadine, Cetirizine): These drugs will suppress the 'wheal and flare' reaction during diagnostic skin testing, leading to a false-negative result. Patients must stop taking antihistamines for 3 to 7 days before testing.
• Tricyclic Antidepressants (e.g., Amitriptyline): These have potent antihistamine properties and can interfere with skin test results for up to 2 weeks.
• H2 Blockers (e.g., Famotidine): May mildly suppress skin test reactivity.
• Systemic Corticosteroids: Long-term use of high-dose steroids can suppress the immune response and the skin’s reactivity to allergens.

There are no direct food-drug interactions with Verbascum Thapsus. However, patients with 'Oral Allergy Syndrome' may experience cross-reactivity between certain fruits and Mullein pollen. It is advised not to eat a heavy meal immediately before an injection to avoid confusion between food-related distress and a systemic reaction.

• St. John's Wort: May theoretically alter the immune response, though clinical data is lacking.
• Herbal Antihistamines (e.g., Butterbur, Quercetin): These should be discontinued before skin testing as they may interfere with diagnostic accuracy.

Verbascum Thapsus administration will increase the levels of allergen-specific IgG antibodies and may temporarily increase specific IgE levels. It does not typically interfere with standard blood chemistry or hematology panels, except for the specific ammonium ion binding activity which may lower serum ammonia levels in laboratory results.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Verbascum Thapsus must NEVER be used in the following circumstances:

1. 1Severe, Unstable Asthma: Patients with an FEV1 consistently below 70% of predicted value are at extreme risk of fatal bronchospasm during immunotherapy.
2. 2Recent Myocardial Infarction (Heart Attack): The stress of a potential systemic reaction and the requirement for epinephrine could be fatal to a compromised heart.
3. 3Hypersensitivity to Diluents: Some extracts contain phenol or glycerin. Patients with a known severe allergy to these preservatives must not receive the extract.
4. 4Beta-Blocker Therapy: As noted, the inability to respond to epinephrine makes immunotherapy unacceptably dangerous.

• Pregnancy: While not strictly contraindicated, starting a new course of immunotherapy during pregnancy is generally avoided due to the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen to the baby).
• Severe Atopic Dermatitis: Extensive skin disease may make it impossible to find a clear area of skin for diagnostic testing.
• Immunodeficiency: Patients with compromised immune systems may not respond to the therapy or may have unpredictable reactions.

Patients allergic to other members of the Scrophulariaceae (Figwort) family may show cross-sensitivity to Verbascum Thapsus. Additionally, there is documented cross-reactivity with certain grass pollens and other weeds in the same ecological niche.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Verbascum Thapsus.

Verbascum Thapsus is classified in FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. The primary concern is not the extract itself, but the potential for a systemic reaction in the mother, which can cause uterine contractions and fetal distress. Maintenance immunotherapy may be continued during pregnancy if the mother is tolerating it well, but doses are typically not increased during this time.

It is not known whether the antigens in Verbascum Thapsus are excreted in human milk. Because most of the components are proteins that would be digested in the infant's stomach, the risk to a nursing infant is considered low. However, the decision to continue immunotherapy while breastfeeding should be made after a risk-benefit discussion with a healthcare provider.

Verbascum Thapsus is safe and effective for diagnostic testing in children as young as infants, though it is rarely performed before age 2. For immunotherapy, the American Academy of Allergy, Asthma & Immunology (AAAAI) suggests that children under age 5 may be difficult to treat because they cannot communicate early symptoms of a reaction. Growth and development are not known to be affected by allergenic extracts.

Clinical studies of Verbascum Thapsus did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, elderly patients have a higher prevalence of comorbid conditions (like heart disease) and are more likely to be on medications (like beta-blockers) that increase the risk of immunotherapy.

In patients with renal impairment, the clearance of inflammatory mediators may be delayed. While no specific dose adjustment is required for the extract, the patient's overall health and ability to tolerate a systemic reaction must be considered.

Given the Ammonium Ion Binding Activity of Verbascum Thapsus, patients with hepatic impairment (e.g., Child-Pugh Class B or C) should be monitored. While the extract is used for allergy, its metabolic effects on nitrogen levels should be noted in the context of liver-related hyperammonemia.

> Important: Special populations require individualized medical assessment.

Verbascum Thapsus operates through a dual-action pharmacological pathway. First, as an allergenic extract, it introduces specific protein antigens (such as Ver t 1) to the immune system. In sensitized individuals, these proteins bind to IgE antibodies on mast cells, causing the release of histamine. In immunotherapy, repeated exposure induces the production of 'blocking' IgG4 antibodies and regulatory T-cells (Tregs), which eventually suppress the allergic response.

Second, the extract functions as a Nitrogen Binding Agent [EPC] through Ammonium Ion Binding Activity [MoA]. It acts as a molecular sieve or chemical binder that sequesters ammonium ions (NH4+). This reduces the concentration of nitrogenous waste products in the blood, which is a critical mechanism for preventing ammonia toxicity in metabolic disorders.

• Onset of Action: For skin testing, the onset is rapid (15–20 minutes). For immunotherapy, the onset of clinical benefit typically takes 3 to 6 months.
• Duration of Effect: The diagnostic wheal lasts for 1–2 hours. The immunological changes from immunotherapy can last for years after treatment is completed.
• Tolerance: Patients develop 'immunological tolerance' rather than drug tolerance; the body becomes less reactive to the allergen over time.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Localized administration) |

| Protein Binding | High (to IgE and IgG4) |

| Half-life | 2–12 hours (systemic components) |

| Tmax | 15–30 minutes (local reaction) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (primary) |

• Molecular Formula: Complex mixture of proteins, glycoproteins, and polysaccharides.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various allergenic fractions.
• Solubility: Highly soluble in aqueous solutions and 50% glycerin.
• Structure: Includes iridoid glycosides (e.g., aucubin), flavonoids, and saponins which contribute to its metabolic binding activity.

Verbascum Thapsus is a member of the Non-Standardized Plant Allergenic Extract class. It is related to other weed extracts like Ambrosia (Ragweed) and Artemisia (Sagebrush).